eCLEAR

The eCLEAR trial investigated whether the early administration of anti-latency reversing therapy and broadly neutralizing antibodies could limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment.

​

This study combined the use of 3BNC117, a potent broadly neutralizing antibody, with a potent latency reversing agent, romidepsin, as a novel approach to reduce the HIV-1 reservoir in ART naïve patients initiating ART.

Subjects continued background ART while receiving the remaining course of romidepsin and/or 3BNC117. The study aimed to evaluate the effect of early viral reactivation and/or administration of potent broadly neutralizing antibodies on the size of the latent HIV-1 reservoir in treatment naïve HIV-1 patients initiating ART; and the safety and tolerability of the Investigational Medicinal Products (IMPs).

​

eCLEAR was jointly coordinated by Aarhus University (Sponsor), Imperial College London and Imperial College NHS Healthcare Trust.

The study was funded by the Danish Government.

​

There were six clinical sites participating in the study in Denmark, and two in the UK: St Mary’s Hospital and Guy’s Hospital in London.

​